Study guide
5.2 Initial ED & Prehospital Pharmacotherapy
AHA ACLS Provider Advanced Cardiovascular Life Support
Track your progress as you read
Finished sections get a check mark.
1 Chapter 1: BLS & High-Quality CPR Foundation
1.1 Chest Compression Mechanics & Performance Metrics 1.2 Chest Compression Fraction & Interruptions 1.3 Two-Rescuer Rotation & Fatigue Prevention 1.4 AED Operation & Special Resuscitation Circumstances
2 Chapter 2: ACLS Adult Cardiac Arrest Algorithm
2.1 Cardiac Arrest Recognition & Systematic Approach 2.2 VF/pVT Management & Defibrillation Energy Protocols 2.3 Asystole & PEA Management 2.4 Epinephrine Dosing & Pharmacodynamics in Arrest 2.5 Antiarrhythmic Drugs: Amiodarone & Lidocaine in Refractory VF/pVT 2.6 Reversible Causes of Arrest: The H's 2.7 Reversible Causes of Arrest: The T's 2.8 Physiological Monitoring & CPR Quality Metrics
3 Chapter 3: Bradycardia Algorithm
3.1 Symptomatic Bradycardia Assessment & Instability Criteria 3.2 Atropine Dosing, Indications & Block Limitations 3.3 Transcutaneous Pacing (TCP) Operation & Management 3.4 Chronotropic Infusion Therapies: Dopamine & Epinephrine
4 Chapter 4: Tachycardia Algorithm
4.1 Tachycardia Triage: Stable vs. Unstable Assessment 4.2 Synchronized Cardioversion Indications, Energy Doses & Sync Mechanics 4.3 Stable Narrow-Complex Tachycardia: Vagal Maneuvers & Adenosine Protocol 4.4 Stable Wide-Complex Tachycardia & Antiarrhythmic Infusions 4.5 Polymorphic VT (Torsades de Pointes) & Magnesium Sulfate Protocol
5 Chapter 5: Acute Coronary Syndrome (ACS)
5.1 ACS Identification, EMS & ED Triage 5.2 Initial ED & Prehospital Pharmacotherapy 5.3 STEMI vs. NSTE-ACS Risk Stratification & Biomarkers 5.4 Reperfusion Strategies & Quality Benchmark Time Goals
6 Chapter 6: Acute Ischemic Stroke
6.1 Stroke Recognition & Out-of-Hospital Assessment 6.2 Emergency Department Evaluation & Diagnostic Time Goals 6.3 Fibrinolytic Therapy & Blood Pressure Management 6.4 Endovascular Therapy (EVT) & Post-Acute Care
7 Chapter 7: Post–Cardiac Arrest Care
7.1 Immediate Post-ROSC Airway & Respiratory Optimization 7.2 Hemodynamic Management & MAP Optimization 7.3 Temperature Control & Targeted Temperature Management (TTM) 7.4 Emergent Coronary Angiography & Multimodal Neuroprognostication
8 Chapter 8: Airway Management & Pharmacology
8.1 Basic Airway Adjuncts & Bag-Mask Ventilation 8.2 Advanced Airways: Supraglottic Devices & Endotracheal Intubation 8.3 Continuous Waveform Capnography 8.4 ACLS Emergency Drug Reference & Administration Routes
9 Chapter 9: High-Performance Team Dynamics & Special Circumstances
9.1 High-Performance Team Dynamics & Communication 9.2 Resuscitation Debriefing & Quality Improvement Metrics 9.3 Special Arrest Circumstances: Cardiac Arrest in Pregnancy 9.4 Special Arrest Circumstances: Opioids, Anaphylaxis, Drowning & Hypothermia
5.2 Initial ED & Prehospital Pharmacotherapy
Key Takeaways Explain This Topic AI
Oxygen should only be administered if the patient is hypoxic (SpO2 <90%), in respiratory distress, or presenting with acute heart failure.
Aspirin 162-325 mg (non-enteric coated) should be chewed immediately for rapid antiplatelet action.
Nitroglycerin sublingual/spray reduces preload but is strictly contraindicated in severe hypotension (SBP <90 mmHg), extreme bradycardia/tachycardia, right ventricular infarction, or recent PDE5 inhibitor use.
Morphine should be reserved for severe ischemic chest pain unrelieved by nitrates due to potential impairment of P2Y12 inhibitor absorption.
Last updated: July 2026
Initial ED & Prehospital Pharmacotherapy
The initial pharmacological management of Acute Coronary Syndrome (ACS) focuses on alleviating ischemia, preventing further thrombus formation, and managing pain. The historical mnemonic "MONA" (Morphine, Oxygen, Nitroglycerin, Aspirin) is still widely taught, but current AHA guidelines have significantly refined the indications and sequencing of these therapies. Understanding the precise appropriate use of each agent is crucial for optimal patient care.
Oxygen Therapy
Historically, supplemental oxygen was routinely administered to all patients with suspected ACS. However, recent evidence suggests that hyperoxia can cause coronary vasoconstriction and increase the production of reactive oxygen species, potentially worsening myocardial injury.
Current Guidelines
Indication: Administer supplemental oxygen ONLY if the patient is hypoxemic (SpO2 < 90%), experiencing significant respiratory distress, or showing signs of heart failure.
Goal: Titrate oxygen to maintain an SpO2 of 90% or higher. Do not over-oxygenate.
Method: Typically initiated via nasal cannula at 2-4 L/min, adjusting as needed based on pulse oximetry.
Aspirin
Aspirin is the cornerstone of early ACS pharmacotherapy. It is an irreversible cyclooxygenase (COX) inhibitor that rapidly blocks the synthesis of thromboxane A2, thereby preventing further platelet aggregation and expansion of the coronary thrombus.
Administration
Dose: 162 mg to 325 mg.
Formulation: Non-enteric coated, chewable aspirin is preferred because chewing facilitates rapid buccal absorption, achieving therapeutic antiplatelet effects within minutes.
Timing: Should be given immediately upon suspicion of ACS, ideally by EMS in the prehospital setting or immediately upon ED arrival.
Contraindications: True severe aspirin allergy (anaphylaxis) or active, severe gastrointestinal bleeding. Note that a history of mild GI intolerance is generally not a contraindication in the setting of acute ACS due to the overwhelming mortality benefit.
Nitroglycerin
Nitroglycerin (NTG) is a potent vasodilator. Its primary mechanism of action in ACS is venodilation, which decreases venous return (preload) to the heart, thereby reducing ventricular wall stress and myocardial oxygen demand. It also provides some direct coronary vasodilation, improving collateral blood flow to ischemic areas.
Administration and Dosing
Route: Sublingual (SL) tablet or translingual spray.
Dose: 0.4 mg every 5 minutes for ongoing chest pain, for a maximum of 3 doses.
Assessment: Blood pressure and pain level must be reassessed before each subsequent dose.
Contraindications and Cautions
The use of NTG requires careful consideration of the patient's hemodynamic status. It is strictly contraindicated in the following situations:
Hypotension: Systolic blood pressure (SBP) < 90 mmHg or a drop of >30 mmHg below baseline.
Extreme Heart Rates: Severe bradycardia (heart rate < 50 bpm) or marked tachycardia (heart rate > 100 bpm in the absence of symptomatic heart failure).
Right Ventricular (RV) Infarction: Suspect RV infarction in patients with an inferior wall STEMI. These patients are highly dependent on adequate preload to maintain cardiac output. Administering a preload reducer like NTG can cause profound and potentially fatal hypotension. Always obtain a right-sided ECG if inferior STEMI is suspected before giving NTG.
Phosphodiesterase-5 (PDE5) Inhibitors: Recent use of PDE5 inhibitors for erectile dysfunction or pulmonary hypertension (e.g., sildenafil or vardenafil within 24 hours; tadalafil within 48 hours). The combination of NTG and a PDE5 inhibitor can lead to severe, refractory hypotension.
Morphine
Morphine sulfate is a potent opioid analgesic and venodilator. It can reduce pain and anxiety, thereby decreasing sympathetic tone and myocardial oxygen demand.
Cautious Use in ACS
While previously a standard therapy, the routine use of morphine in ACS is now approached with caution. Recent studies have raised concerns regarding its interaction with oral P2Y12 receptor inhibitors (such as clopidogrel, ticagrelor, and prasugrel).
Interaction: Morphine can delay the absorption and onset of action of these crucial antiplatelet agents, potentially reducing their efficacy during the acute phase of myocardial infarction.
Current Recommendation: Morphine is indicated for patients with severe ischemic chest pain that is unrelieved by initial therapies , specifically after a trial of sublingual nitroglycerin (if not contraindicated). It is no longer considered a first-line agent for all ACS patients.
Dosing: Typically administered intravenously in small increments (e.g., 2-4 mg IV initially, followed by 2-8 mg every 5-15 minutes as needed), carefully monitoring for respiratory depression and hypotension.
In summary, the initial pharmacological approach to ACS prioritizes immediate antiplatelet therapy with aspirin and targeted ischemia relief with nitroglycerin, while reserving oxygen for hypoxic patients and morphine for refractory pain, always mindful of critical contraindications.